Trump's Executive Order Opens Door to Psychedelic Medicine Future

The Executive Order That Changed Psychedelic Policy

In a surprising move during the weekend celebrating 'Bicycle Day' – the anniversary of the first LSD trip – Donald Trump signed a landmark executive order to accelerate research into hallucinogens and increase access to them. The scene was surreal as Trump joked, 'Can I have some, please?' when discussing ibogaine, a lesser-known psychedelic known for its 12-hour trips that often provide visions of traumatic personal memories.

Accelerated FDA Review Process

Thanks to the order, the US Food and Drug Administration (FDA) will fast-track the reviews of three incoming psychedelic drug candidate applications that have already received breakthrough therapy designations. These are likely to be psilocybin for two types of depression and MDMA for PTSD, a prior application for which was rejected by the FDA in 2024. This move represents the biggest greenlight the potential multibillion-dollar market has yet received, causing psychedelic company stocks to soar.

Financial Implications of the Psychedelic Market

The executive order has significant financial implications for the emerging psychedelic industry. Industry analyst Josh Hardman noted that the expected issuance of these vouchers shows just how much the White House has changed its mind on psychedelics in the last six months. The Department of Health and Human Services also announced a new $139m initiative to help spur new, effective therapies for behavioral health, including the safe use of psychedelics, with at least $50m earmarked to match state psychedelic research initiatives.

Industry and Regulatory Transformation

This executive order marks a significant shift in the approach to psychedelic substances in the United States, which have been federally illegal since Richard Nixon passed the 1970 Controlled Substances Act. The order states that investigational psychedelic drugs will become available under 'right to try' legislation, which is typically reserved for terminally ill patients and those who have tried all approved treatment options. However, this sets up a potential clash with the Drug Enforcement Administration (DEA), which has previously stated that schedule I compounds are ineligible for right to try.

Future Outlook for Psychedelic Medicine

The future of psychedelic medicine in the US appears to be accelerating, but with significant challenges remaining. While Trump indicated his administration is already working on rescheduling efforts, which would require approval from the DEA, concerns remain about pharmaceutical and commercial interests being the primary beneficiaries of the order. Indigenous communities that have stewarded psychedelics like ibogaine and psilocybin worry they won't be fairly compensated for their knowledge. As psychedelic reform advocate Ismail Ali noted, 'It is a substantial threshold moment,' but 'if you're looking at the US federal government for the full liberation of these plants, you're probably looking in the wrong place.' The coming years will determine whether this marks the beginning of a truly accessible psychedelic medicine future or another chapter in extraction and commercialization.